Treating the diabetic patient: Appropriate care for glycemic control and cardiovascular disease risk factors

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 6, 2003, Pages

  Zarich, Stuart W ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIDGEPORT HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Dyslipidemia; Glucose intolerence; Glycemic control; Hypertension

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN; METFORMIN; MEVINOLIN; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; RANOLAZINE; ROSIGLITAZONE; SIBRAFIBAN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TRIACYLGLYCEROL; TRIMETAZIDINE; UNINDEXED DRUG;

AGING; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIET THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DYSLIPIDEMIA; EPIDEMIC; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; LIFESTYLE; MICROANGIOPATHY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT CARE; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING; UNITED STATES; WEIGHT REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; RISK FACTORS;

EID: 0346271517     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979;2:120-126.
2. Mokdad Ah, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
4. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb. 1992;12:647-656.
5. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995;44:1386-1391.
6. Varo N, Vincent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. Circulation. 2003;107:2664-2669.
7. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation. 2002;106:2760-2763.
8. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
9. Knatterud GL, Klimt CR, Levin ME, et al. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA. 1978;240:37-42.
10. Cleveland JC Jr, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation. 1997;96:29-32.
11. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999;33:119-124.
12. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865.
13. McGuire DK, Newby LK, Bapkar MV, Moliterno DJ, et al. Diabetes doubles the risk of death after acute coronary syndrome: Insights from SYMPHONY: A large international trial. JACC. 2001;37:372A.
14. Sauer WH, Berlin JA, Kimmel SE. Thiazolidinediones and prevention of myocardial infarction with type 2 diabetes. Circulation. 2002;106:562.
15. Marx N, Libby F, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk. 2001;8:203-210.
16. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71.
17. Yue T, Chen J, Boa W, Narayanan PK, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2001;104:2588-2594.
18. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126-3132.
19. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. JAMA. 2002;287:360-376.
20. UK Prospective Diabetes Study (UKPDS) Group. Overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
21. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702.
22. Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of an intravenous infusion of a potassium-insulin-glucose solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962;9:166-181.
23. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;1:107-114.
24. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation 1998;98:2227-2234.
25. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
26. Conti R. Partial fatty acid oxidation (pFOX) inhibition: A new therapy for chronic stable angina. Clin Cardiol. 2003;26:161-162.
27. Ballantyne CM, Olson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046-3051.
28. Lamarche B, St-Pierre AC, Ruel IL, et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 2001;17:859-865.
29. Dichtl W, Nilsson L, Goncalves I, et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res. 1999;84:1085-1094.
30. Herman WH, Alexander CM, Cook JR, et al. Effect of simvastatin treatment on cardiovascular resources utilization in impaired fasting glucose and diabetes; findings from the Scandinavian Simvastatin Survival Study. Diabetes Care. 1999;22:1771-1778.
31. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
32. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-1009.
33. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary heart events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;97:1453-1460.
34. Robins SJ, Collins D, Witters JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events; VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585-1591.
35. Manninen V, Tenkanen L, Koskinen F, et al. joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
36. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease; the Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102:21-27.
37. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
38. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effects of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: The DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001;24:1335.
39. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947-952.
40. Schaefer E, Gould E. Rosiglitazone increases high-density lipoprotein cholesterol levels in patients with type 2 diabetes. J Am Coll Cardiol. 2003;316A.
41. Kirpichnikov D, McFarlane S, Sowers JR. Metformin: An update. Ann Intern Med. 2002;137:25-33.
42. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003;138:593-602.
43. Zandbergen A, Baggen M, Lamberts SN, et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med. 2003;139:90-96.
44. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
45. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet. 1999;353:611-616.
46. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
47. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:596-603.
48. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Invention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
49. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Study Group. BMJ. 1998;317:703-713.
50. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998;351:1755-1762.
51. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2991.
52. Yusuf S, Gerstein H. Hoggwerf B, et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
53. Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U. S. adults with diabetes, 1988-1994. Am J Prev Med. 2002;22:42-48.
54. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
55. Tanasescu M, Leitzmann M, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation. 2003;107:2435-2439.
56. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;347:709-715.
57. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
58. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002; 51:2796-2803.
59. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes: the STOP-NIDDM randomised trial. Lancet. 2002; 359:2072-2077.
60. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-494.
61. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:393-403.
62. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106:2827-2835.
63. Antiplatelet Trialist's Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.